Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors.
Observational study · 1983
- What was studied
- 67 withdrawal patients enrolled; 49 evaluable
- Main finding
- An uncontrolled withdrawal report described improvement in 48 of 49 evaluable patients after DSIP, but 18 of 67 enrolled patients were not evaluable.
Reported findings and study design
An uncontrolled withdrawal report described improvement in 48 of 49 evaluable patients after DSIP, but 18 of 67 enrolled patients were not evaluable.
67 patients with withdrawal symptoms: alcohol 28, opiates 39; DSIP was the sole reported treatment.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported beneficial response | 48/49 evaluable | 22 alcohol-withdrawal patients and 26/27 opiate-withdrawal patients |
| Attrition | 18/67 not evaluable; abstract reports 27% | 49 patients contributed to the response analysis |
| Major adverse effects | None reported | Limited uncontrolled clinical series |
| Studied regimen | 25 nmol/kg intravenously |
The evaluable-patient response excludes substantial attrition and has no placebo comparator. It does not establish a safe or effective withdrawal treatment.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- No control group and substantial exclusion/loss prevent causal conclusions. Not a basis for self-treatment of withdrawal.
Source details
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Sources checked
Citation
Dick P, Grandjean ME, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology 10(4):205-208
Study source ↗ · DOI 10.1159/000118012 · Bibliography entry · Link to this summary